Abiopharma

🔍 Posard Matthew L. (Director)

Company: Nautilus Biotechnology, Inc. (NAUT)

Report Date: 2026-06-18

Detailed Transactions and Holdings:

• Acquired 45,000 shares of Stock Option (Right to Buy) at $2.28 per share (Derivative)
  Date: 2026-06-18 | Code: A | Expires: 2036-06-18 | equity_swap_involved: 0 | shares_owned_after: 45,000.00 | transaction_form_type: 4 | Footnotes: F1

Footnotes:

• F1: Subject to reporting person's continuous status as a "Service Provider" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, one-twelfth (1/12th) of the shares subject to the Option shall vest on a monthly basis following the date of grant on the same day of the month as such grant date (or on the last day of the month, if there is no corresponding day in such month).